Stock rose 6.5% following positive phase III trial results demonstrating ivonescimab's superiority over an established competitor in biliary tract cancer. Results validate the drug's broader development potential across multiple cancer indications (CRC, genitourinary cancer), expanding addressable market and strengthening the company's pipeline.
Faces high regulatory risk with FDA decision by November 14, 2026. Lead candidate ivonescimab lacks statistically significant overall survival benefit in non-Chinese populations, which FDA requires for approval. Stock could drop significantly (20%+) if rejected, though upside exists if approved.
Articles that tag SMMT but are mainly about other companies.
Slid 10.4% in sell-the-news reaction to ASCO data; H.C. Wainwright downgraded to Neutral and Bernstein reiterated Underperform
Mentioned only as a top holding of Superstring Capital ($16.93M, 12.1% of AUM) with no specific news or analysis provided in the article.
Stock fell 27.82% following Q1 financial results announcement
Cratered 23.7% after fresh ivonescimab data missed statistical significance versus Keytruda
28.32% weekly gain following positive Phase 3 clinical trial results with final endpoint data
Stock surged 12.95%, the top gainer among Russell 1000 stocks.
Articles and sentiment ratings from Massive / Polygon. Sentiment is the provider's model rating for this company, not Gainbot's view.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology
